
What is claimed is:

1. ~~A method of treating systemic lupus erythematosus or lupus nephritis in a patient, said method comprising administering to the patient~~ Use of a therapeutically effective amount of a compound comprising a selective Bcl-2 inhibitor, in the manufacture of a medicament for treating systemic lupus erythematosus or lupus nephritis in a patient.

2. The ~~method~~ use of claim 1 wherein the selective Bcl-2 inhibitor is a compound of Formula (I),



(I),

wherein

A^1 is N or CH;

B^1 is OR^1 or NHR^1;

Y^1 is CN, NO_2, CF_3, F or Cl;

R^1 is $(CH_2)_nR^2$;

R^2 is cycloalkyl or heterocyclyl; wherein the heterocyclyl and cycloalkyl are optionally substituted with one or more independently selected R^4, OR^4, OH, CN, or F;

R^3 is heteroaryl; wherein the heteroaryl is optionally substituted with one or more independently selected NH_2, Cl, or F;

R^4 is alkyl, cycloalkyl, heterocyclyl, or spiroheterocyclyl; wherein the alkyl is optionally substituted with one or more F;

R^5 is deuterium;

each R^6 is independently selected from CH_3, spirocyclopropyl and OH;

m is 0, 1, 2, 3, 4, 5, or 6;

n is 0 or 1; and

p is 0, 1, or 2,

or a pharmaceutically acceptable salt thereof.

3. The ~~method~~ use of claim 2, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a Bcl-2 binding affinity (K_i) value of less than about 1 nanomolar.

4. The ~~method~~ use of claim 3, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a Bcl-2 binding affinity (K_i) value of less than about 100 picomolar.

5. The ~~method~~ use of claim 2, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a binding affinity (K_i) for Bcl-2 that is at least 500 times less than the binding affinity (K_i) for Bcl-x_L.

6. The ~~method~~ use of claim 2, wherein the compound is selected from:

N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-[(6-fluoro-1H-indazol-4-yl)oxy]benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-indazol-4-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; and

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide.

7. ~~A method of treating Sjogren's Syndrome in a patient, said method comprising administering to the patient a therapeutically effective amount~~ Use of a compound comprising a selective Bcl-2 inhibitor, in the manufacture of a medicament for treating Sjogren's Syndrome in a patient.

8. The ~~method~~ use of claim 7, wherein the selective Bcl-2 inhibitor is a compound of Formula (I),

9. The ~~method~~ use of claim 8, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a Bcl-2 binding affinity (K_i) of less than about 1 nanomolar.

10. The ~~method~~ use of claim 9, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a Bcl-2 binding affinity (K_i) of less than about 100 picomolar.

11. The ~~method~~ use of claim 8, wherein the compound that selectively inhibits the activity of a Bcl-2 protein has a binding affinity (K_i) for Bcl-2 that is at least 500 times less than the binding affinity (K_i) for Bcl-x_L.

12. The ~~method~~ use of claim 8, wherein the compound is selected from:

N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-[(6-fluoro-1H-indazol-4-yl)oxy]benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1H-indazol-4-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-[(6-fluoro-1H-indol-5-yl)oxy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide;

2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)benzamide;